FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progresse...
· Sog‘liq · Manba: U.S. Food and Drug Administration (FDA) · ingliz tili